EARS News and Press, Auris Medical Holding AG From 10/13/20

4 Penny Stocks To Buy Under $4.25 Right Now Looking for penny stocks to buy today? You’re not alone. One of the most popular topics daily is finding an answer to 1 question. “ What are the best penny stocks to buy today? “ Of course, the process is e...

Nano-cap Auris Medical (EARS) soars 75% in premarket, on initiation of Part B of its Phase 2 TRAVERS trial evaluating AM-125 (intranasal betahistine) in acute vertigo following neurosurgery.In Part B of the TRAVERS trial, the Company will enroll 72 patients. Improvement in the ...

Hamilton, Bermuda, October 13, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the first patient has be...

The following slide deck was published by Auris Medical Holding Ltd. in conjunction with their 2020 Q2 earnings Read more ...

Auris Medical Holding Ltd. (EARS) Q2 2020 Earnings Conference Call September 17, 2020 08:30 AM ET Company Participants Thomas Meyer - Founder, Chairman, CEO & MD Elmar Schaerli - CFO Conference Call Participants Maxim Jacobs - Edison Investment Research Limited Present...

Auris Medical (NASDAQ: EARS ) 1H results  (CHF): Revenues: 0; Net Loss: (2.7M) improved 27%; Loss Per Share: (0.58) (+65.0%); Quick Assets: 0.04M. More news on: Auris Medical Holding Ltd., Stocks on the move, Earnings news and commentary, Healthcare stocks news, , Read mor...

Advancing Phase 2 trial with AM-125 in acute vertigo based on positive interim data Positive outcome from AM-201 trial in prevention of antipsychotic-induced weight gain Addition of new intranasal program with development of drug-free spray for protection against airborne pathogens and a...

Hamilton, Bermuda, September 11, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that it will provide a busi...

Development of AM-301 nasal spray initiated with aim of regulatory submission in 2021 Key component of AM-301 shown to reduce SARS-CoV-2 viral infectious load in vitro by up to 99% Creation of dedicated subsidiary, Altamira Medica Ltd, to focus solely on AM-301 development program CHF 1...

Tortoise Acquisition (NYSE: SHLL ) -9% . More news on: Tortoise Acquisition Corp., Auris Medical Holding Ltd., Digital Turbine, Inc., Stocks on the move, , Read more ...